IGF1R and colorectal carcinoma: In conclusion, this study demonstrated that MK-0646, a novel humanized IGF-1R monoclonal antibody, has comparable antitumor effects to IGF-1R small molecule inhibitor OSI-906, and may be a potential novel targeted therapy against IGF-1R-dependent subset of human CRC.